Recursion
Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.
Few AI drug discovery companies can point to clinical-stage programs and a partner exercising an option — Genentech's Q2 2026 neuroscience milestone is the strongest proof point in the space right now. The catch is access and verification: you partner with Recursion, you don't subscribe to it, and July 2026 allegations about capability claims mean diligence should go past the deck.
Verified 18h ago · liveness 62/100 · cite: rightaichoice.com/tools/recursion
- Large pharma seeking an external AI-native discovery engine on a defined therapeutic problem
- Biotech with capital for multi-year, bespoke R&D partnerships
- Investors underwriting clinical-stage AI pipelines with near-term readouts
- Oncology and rare disease teams needing novel targets and phenotypic screening
- Startups without the budget for a multi-year partnership
- Teams that need a licensable platform or API they can run themselves
- Genomics-first researchers — the core modality is cellular imaging, not sequencing
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip Recursion if you want to buy discovery software you can run yourself this quarter — its output is a partnered clinical pipeline, and engagement runs through multi-year pharma, technology or data collaborations rather than a purchasable license.
Partnership engagements are bespoke, so legal, diligence and joint-governance overhead lands on your side before any molecule work starts
Recursion prices as a partnership, not a subscription, so the comparison set is other clinical-stage techbio companies and traditional CRO-plus-discovery arrangements rather than SaaS tiers. The relevant budget question is whether a multi-year, bespoke R&D collaboration is cheaper and faster than building the same phenotypic screening and generative chemistry capability in-house.
In short
Recursion — Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments. Best for Large pharma seeking an external AI-native discovery engine on a defined therapeutic problem, Biotech with capital for multi-year, bespoke R&D partnerships, Investors underwriting clinical-stage AI pipelines with near-term readouts. Contact Sales pricing.
What's new in Recursion
Checked 8 days agoAcross the latest 1 update: 1 launch.
What people actually say about Recursion — is it worth it?
We ran a structured research pass across product reviews, community discussions, and post-purchase forum threads to surface the patterns vendors won't publish themselves. Below: the recurring strengths, the hidden costs people mention most, and the cohort that consistently regrets adopting this tool.
68 mentions across 4 sources (Reddit, Hacker News, Stack Overflow, Lemmy) · researched Jul 31, 2026.
Average across the 4 sources that answered — each source counts once, not each post.
- +Massive dataset integration (50+ petabytes) for deep biological insights
- +Automated wet lab enables millions of experiments weekly, accelerating discovery
- +Strategic NVIDIA partnership provides cutting-edge compute power
- +Multiple clinical trials with early positive data validate approach
- +End-to-end capability from target ID to clinical trials
- −Highly complex platform requires advanced technical expertise to use
- −Proprietary algorithms and data limit external validation and trust
- −Clinical success still unproven; most programs in early phases
- −High cost likely restricts access to well-funded organizations
- −Community feedback is sparse; minimal direct user experiences shared
Viability Score
How well maintained and how widely used is Recursion? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- Recursion OS AI-native drug discovery and development platform
- Wet and dry lab-in-the-loop continuous learning system
- Automated wet labs with robotics and computer vision
- Up to 2 million weekly cell experiments feeding model training
- 50+ petabyte proprietary phenomics, transcriptomics, proteomics and ADME dataset
- Generative de novo chemistry for molecule design
- Target identification and validation via machine learning
- High-throughput phenotypic screening of cellular images
- In-silico filtering to synthetically accessible compound shortlists
- Translational clinical tools connecting preclinical models to trials
- De-identified patient data integration for precision medicine
- Clinical pipeline: REC-4881 (Phase 2, FAP), REC-3565 and REC-1245 (Phase 1)
- Named trials: TUPELO, ELUCIDATE, DAHLIA, EXCELERIZE, ENLYGHT, ZINNIA
- Pharmaceutical, technology and data partnerships
- Genentech neuroscience collaboration with option exercised Q2 2026
About Recursion
Recursion is a clinical-stage techbio company, not a software vendor. Its Recursion OS platform runs a wet-and-dry lab-in-the-loop: robotics and computer vision image cells at scale while machine learning models learn from every result, feeding up to 2 million weekly experiments into a 50+ petabyte proprietary dataset spanning phenomics, transcriptomics, proteomics, ADME and de-identified patient data. That loop drives target identification, generative de novo chemistry and translational work from hit identification through IND-enabling studies. Recursion claims its integrated system narrows millions of molecules to a synthetically accessible short list before anything reaches a lab, and that across programs it has advanced novel candidates after synthesizing only around 300 compounds — roughly 90% fewer than the industry average. The commercial output is a pipeline, not a license. Programs span oncology, familial adenomatous polyposis and hypophosphatasia, with named trials TUPELO, ELUCIDATE, DAHLIA, EXCELERIZE, ENLYGHT and ZINNIA. REC-4881, a MEK1/2 inhibitor in Phase 2 for FAP, is a flagship; REC-3565 and REC-1245 are in Phase 1. Engagement runs through pharma, technology and data partnerships — Genentech exercised its first neuroscience option in Q2 2026. Set expectations: if you're a biopharma scouting an AI-native discovery partner or an investor underwriting clinical-stage AI pipelines, Recursion belongs on the list. If you want an API key and a monthly plan, this isn't that kind of company.
Behind the Verdict
Pick Recursion when the question is 'who can run a large, image-based phenotypic screen and actually follow it into the clinic?' The 50+ petabyte dataset and the automated labs behind it are the reason pharma partners sign up, not the model architecture. The Genentech neuroscience option, exercised in Q2 2026, is the detail I'd put in front of a skeptical investment committee. Partners with full visibility into the data don't exercise options on a whim. Layer on REC-4881 in Phase 2 for FAP and two Phase 1 assets, and you have readouts rather than promises. The 300-compounds-versus-industry-average claim is worth interrogating in a diligence call. It's a real efficiency signal if it holds across programs, and Recursion publishes the framing rather than a full dataset. Which brings up July 2026. A blog post alleging the company misrepresents capabilities got traction on Hacker News. We don't treat a single blog post as proof of anything, but for a company whose entire pitch is 'trust our data,' it justifies asking for raw experimental throughput numbers and partner-verified results. Pass if you need a computational platform you can license and run yourself. Recursion is a biotech with a platform; the output is molecules and partnerships, not seats. Genomics-first teams should also look elsewhere — the core modality is cellular imaging, not sequencing. Closest alternatives depend on what you're buying. For a discovery partner, the comparison is other techbio players with wet-lab loops. For pipeline risk, it's every clinical-stage biotech. Recursion's edge is that the two are the same company. One practical caveat: engagement is slow and bespoke. If your timeline is a quarter, this isn't the partner. If it's three years and the therapeutic problem is genuinely novel,
Researching Recursion? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas Recursion actually fits — and what changes day-one when you adopt it.
You bring a defined neuroscience or oncology problem and map it against Recursion's phenomics dataset and automated screening to find novel targets you would not have generated internally.
Outcome: A jointly advanced program — the Genentech collaboration optioning its first neuroscience target in Q2 2026 is the reference case for how this plays out.
You underwrite the pipeline rather than a platform: REC-4881 in advanced solid tumors, REC-3565 now dosing patients in Phase 1 in relapsed or refractory B-cell lymphomas, REC-1245 in Phase 1.
Outcome: Readouts from these trials, plus programs in familial adenomatous polyposis and hypophosphatasia, are the events that move the thesis.
You use high-throughput cellular imaging and machine learning to find biological disruptions driving a rare indication such as hypophosphatasia where traditional target discovery has stalled.
Outcome: A candidate taken from hit identification through IND-enabling studies with automated wet-lab validation at each step.
Use Cases
- Identify novel drug targets by analyzing phenomics data from millions of cell imaging experiments.
- Design optimized preclinical molecules using generative AI trained on proprietary datasets.
- Accelerate hit-to-lead and IND-enabling studies with automated wet-lab validation.
- Partner with Recursion to co-develop treatments for oncology or rare diseases.
- De-risk pipeline decisions with AI-driven predictive models and translational data.
Models Under the Hood
as of 2026-10-15
Limitations
- Recursion operates as a clinical-stage drug discovery company; engagement is via pharmaceutical, technology and data partnerships, such as the Genentech neuroscience collaboration where Genentech exercised the first target option in Q2 2026.
- The capital and time required to run a partnership at that scale means this option is realistically available to large pharma and well-funded biotech, not to small teams.
- A July 2026 blog post alleging capability misrepresentation sparked community discussion, but no verified facts are presented in the evidence to support that claim; treat it as a prompt for independent diligence on pipeline and partnership economics.
as of 2026-09-30
Verification history
We have re-verified Recursion 21 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 21 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where Recursion's pricing actually pencils out — and where peers do it cheaper.
Recursion prices as a partnership, not a subscription, so the comparison set is other clinical-stage techbio companies and traditional CRO-plus-discovery arrangements rather than SaaS tiers. The relevant budget question is whether a multi-year, bespoke R&D collaboration is cheaper and faster than building the same phenotypic screening and generative chemistry capability in-house.
Setup time & first value
How long it actually takes to get something useful out of Recursion — broken out by persona, not the marketing-page minute.
For a pharma or biotech partner: expect months, not days — scoping a therapeutic problem, legal and diligence work, and joint governance come before any molecule work. For an investor: no setup, the pipeline and trial readouts are public. For a researcher wanting tooling: there is no setup path, because Recursion does not sell access to the platform.
Switching to or from Recursion
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From in-house phenotypic screening: pair your assay strategy with Recursion's automated labs to reach experiment volumes your internal robotics cannot.
- →From a traditional CRO discovery arrangement: move hit identification and generative chemistry into a partnership where the screening data compounds into a proprietary dataset.
- ↗To a purchasable AI discovery software vendor: if you need to run the models yourself, you are trading Recursion's 50+ PB proprietary dataset for tooling you control.
- ↗To an academic or consortium screening core: lower cost, but you lose the lab-in-the-loop feedback between automated experiments and ML models.
Integrations
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “Recursion”, and we withheld 6: 6 could not be judged, because “Recursion” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about Recursion.
Official links
Tools that pair well with Recursion
Common stack mates teams adopt alongside Recursion, with the specific reason each pairing earns its keep.
Exscientia
AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.
Recursion Pharmaceuticals
Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.
Iktos
Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.
Featured Head-to-Head Comparisons
Codametrix vs Recursion
If you're a pharma company looking to accelerate early-stage drug discovery with a platform that combines massive phenomics data, automated wet labs, and AI modeling, Recursion is your choice. For large health systems aiming to cut coding costs by 30% and reduce denials by 60% with enterprise-wide automation, CodaMetrix leads. These tools serve completely different markets, so your decision hinges on whether you prioritize drug R&D or revenue cycle efficiency.
Juno vs Recursion
Recursion and Juno serve entirely different needs. Recursion is a high-investment platform for pharmaceutical companies aiming to accelerate drug discovery with massive datasets and wet-lab validation. Juno is a freemium, user-friendly app for individuals managing chronic illnesses to track symptoms and generate reports for doctors. If you're a patient, Juno is the clear choice; if you're a pharma R&D team, Recursion's custom partnership is the path forward.
Lojong vs Recursion
If you're a pharma company aiming to slash drug failure rates, Recursion's integrated platform and clinical assets are unmatched, but it requires deep partnership and investment. For personal mental wellness, Lojong offers an accessible, Portuguese-language meditation app with proven user outcomes. These tools serve entirely different needs — choose based on whether your goal is therapeutic discovery or personal tranquility.
Recursion vs Semrush One
These tools are incomparable: Recursion is a techbio platform for drug discovery with custom pricing and a massive wet lab, while Semrush One is a SaaS for SEO and AI search visibility with fixed enterprise pricing. Your choice depends entirely on your domain—biotech vs. digital marketing. Neither is a substitute for the other; pick Recursion if you're a pharma company seeking novel therapeutics, or Semrush One if you need to optimize brand presence across traditional and AI search.
Alternatives to Recursion
View all
Exscientia
AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.
Recursion Pharmaceuticals
Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.
Frequently Asked Questions
Categories
Best-of guides
Used Recursion? Help shape our editorial sentiment research.